Cresco Labs (CRLBF) Stock Price, News & Analysis

Company Overview

Cresco Labs is a vertically integrated, multi-state cannabis operator in the United States. The company engages in the cultivation, manufacturing and distribution of a broad range of cannabis products, including flower, pre-rolled joints, concentrates, vaporizers, edibles and tinctures. Cresco Labs’ operations span cultivation facilities, processing laboratories and a network of wholesale distribution centers that supply licensed dispensaries and retail outlets across key cannabis markets.

The company’s product portfolio is organized under several branded platforms, such as MÜV, Reserve and High Supply, each designed to address different segments of the adult-use and medical cannabis markets. Cresco Labs also operates retail dispensaries under the Sunnyside banner, providing consumers with standardized dispensary experiences and educational resources aimed at promoting responsible consumption. In addition to branded consumer products, the company offers white-label manufacturing and distribution services to third-party cannabis operators seeking scalable production solutions.

Founded by industry veterans Charlie Bachtell and Joe Caltabiano, Cresco Labs traces its origins to a 2013 cultivation and processing venture in Illinois. Since rebranding as Cresco Labs, the company has pursued a growth-through-acquisition strategy, adding licensed operations in states such as Florida, Pennsylvania, Massachusetts, Michigan, California, Colorado, Ohio, Nevada and Arizona. Key acquisitions have included regional producers and dispensary chains, enabling Cresco Labs to establish a diversified footprint and centralized supply chain infrastructure.

Under its leadership team, Cresco Labs emphasizes rigorous quality control, regulatory compliance and operational efficiency. The company maintains in-house scientific teams to oversee product development and analytical testing, ensuring consistency across its market portfolio. With expanding retail and wholesale channels, Cresco Labs aims to support long-term market growth by balancing consumer-driven innovation with adherence to evolving state regulations.

Key Stats

• Today's Range: $0.74 to $0.79
• 50-Day Range: $0.64 to $0.83
• 52-Week Range: $0.59 to $2.30
• Volume: 370,575 shs
• Average Volume: 452,295 shs
• Market Capitalization: $392.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Cresco Labs Stock Analysis - MarketRank™

Cresco Labs scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Buy

Consensus Rating

Cresco Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cresco Labs has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cresco Labs are expected to grow in the coming year, from ($0.04) to ($0.02) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cresco Labs is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cresco Labs is -2.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cresco Labs has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.28% of the float of Cresco Labs has been sold short.

Short Interest Ratio / Days to Cover

Cresco Labs has a short interest ratio ("days to cover") of 2.27, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cresco Labs has recently increased by 26.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cresco Labs does not currently pay a dividend.

Dividend Growth

Cresco Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.87

News Sentiment

Cresco Labs has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cresco Labs this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for CRLBF on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

4 people have added Cresco Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cresco Labs insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.05% of the stock of Cresco Labs is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/06/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CRLBF
• CIK: 1832928
• Web: www.crescolabs.com
• Phone: 312-929-0993
• Fax: N/A
• Employees: 2,900
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): ($0.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$135.41 million
• Net Margins: -15.50%
• Pretax Margin: -15.92%
• Return on Equity: -7.53%
• Return on Assets: -1.68%

Debt

• Debt-to-Equity Ratio: 1.66
• Current Ratio: 1.78
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $655.85 million
• Price / Sales: 0.60
• Cash Flow: $0.04 per share
• Price / Cash Flow: 20.25
• Book Value: $0.50 per share
• Price / Book: 1.56

Miscellaneous

• Outstanding Shares: 502,760,000
• Free Float: N/A
• Market Cap: $392.15 million
• Optionable: Not Optionable
• Beta: 1.57